How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) posted its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. During the same period in the previous year, the firm posted ($0.12) earnings per share.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX) , Matinas BioPharma (MTNB) , OPKO Health (OPK) , Rigel Pharmaceuticals (RIGL) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Aeterna Zentaris (AEZS) , Dynavax Technologies (DVAX) , Vaxart (VXRT) and Geron (GERN) .

NASDAQ:VBLT

Vascular Biogenics (VBLT) Stock Price, News & Analysis

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)

Free VBLT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $5.34
▼
$6.74
50-Day Range: $0.16
▼
$5.46
52-Week Range: $0.10
▼
$6.74

Volume: 161,505 shs
Average Volume: 2.19 million shs
Market Capitalization: $423.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Earnings Headlines Social Media

Get Vascular Biogenics alerts:

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Vascular Biogenics Stock (NASDAQ:VBLT)

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

VBLT Stock News Headlines

November 3, 2023 | msn.com

Vascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26

October 16, 2023 | finance.yahoo.com

Notable Labs Closes Merger Transaction With VBL Therapeutics

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

October 12, 2023 | finance.yahoo.com

VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting

October 4, 2023 | finance.yahoo.com

VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting

September 9, 2023 | finance.yahoo.com

Vascular Biogenics Rises on Presentation Hype

September 6, 2023 | finance.yahoo.com

VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC

August 28, 2023 | businesswire.com

VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

August 28, 2023 | businesswire.com

VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT

August 14, 2023 | finance.yahoo.com

VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

July 23, 2023 | fool.com

Vascular Biogenics (NASDAQ: VBLT)

May 15, 2023 | finance.yahoo.com

VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

April 4, 2023 | benzinga.com

Vascular Biogenics Stock (NASDAQ:VBLT), Dividends

March 17, 2023 | finance.yahoo.com

Vascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)

March 14, 2023 | finance.yahoo.com

VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

March 9, 2023 | finance.yahoo.com

VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash

February 27, 2023 | prnewswire.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vascular Biogenics Ltd. - VBLT

February 23, 2023 | technews.tmcnet.com

VBLT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Vascular Biogenics Ltd. Is Fair to Shareholders

February 23, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vascular Biogenics Ltd. Merger

February 23, 2023 | marketwatch.com

Vascular Biogenics Shares Jump Premarket on Reverse Merger Plans >VBLT

February 23, 2023 | msn.com

Vascular Biogenics rises 85% on all-stock merger deal with Notable Labs

February 23, 2023 | investorplace.com

Why Is Vascular Biogenics (VBLT) Stock Up 52%?

February 16, 2023 | finance.yahoo.com

VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash

November 10, 2022 | finance.yahoo.com

OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates

September 2, 2022 | finance.yahoo.com

Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07

September 1, 2022 | finance.yahoo.com

VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

See More Headlines

Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/16/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VBLT
Previous Symbol: NASDAQ:VBLX
CUSIP: N/A
CIK: 1603207
Web: www.vblrx.com
Phone: (728) 993-5000
Fax: 972-8993-5001
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-32,300,000.00
Net Margins: N/A
Pretax Margin: -3,317.05%
Return on Equity: -73.45%
Return on Assets: -54.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.63
Quick Ratio: 4.63

Sales & Book Value

Annual Sales: $660,000.00
Price / Sales: 642.29
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.32 per share
Price / Book: 17.06

Miscellaneous

Outstanding Shares: 77,640,000
Free Float: 72,881,000
Market Cap: $423.91 million
Optionable: Optionable
Beta: 0.77

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Prof. Dror Harats M.D. (Age 66)
CEO & Director
Comp: $444.33k
Mr. Samuel Backenroth (Age 39)
Chief Financial Officer
Comp: $410k
Dr. Eyal Breitbart Ph.D. (Age 56)
Sr. VP of Research & Operations
Advocate Ayelet Horn (Age 52)
Gen. Counsel
Dr. Erez Feige M.B.A. (Age 49)
Ph.D., Sr. VP of Bus. Operations

Key Competitors

View All Competitors

VBLT Stock Analysis - Frequently Asked Questions

How were Vascular Biogenics' earnings last quarter?: Vascular Biogenics Ltd. (NASDAQ:VBLT) posted its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. During the same period in the previous year, the firm posted ($0.12) earnings per share.
What other stocks do shareholders of Vascular Biogenics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

This page (NASDAQ:VBLT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vascular Biogenics (VBLT) Stock Price, News & Analysis

About Vascular Biogenics Stock (NASDAQ:VBLT)

VBLT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

VBLT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info